No Data
No Data
Mayinglong Pharmaceutical Group (SHSE:600993) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Calculating The Fair Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)
Founder Securities: Traditional Chinese medicine sector H1 performance is under short-term pressure. The performance of branded OTC companies is better than the industry as a whole.
Due to the impact of high base in the same period of 23Q2 and external factors such as centralized procurement and same-price policy, the performance of the traditional Chinese medicine sector in Q2 is under pressure compared to the same period last year, and it also declined compared to Q1.
Investors Can Find Comfort In Mayinglong Pharmaceutical Group's (SHSE:600993) Earnings Quality
Mayinglong Pharmaceutical's H1 Profit Rises 11%, Operating Income Jumps 18%
Mayinglong Pharmaceutical Group's 2024 semi-annual report
No Data
No Data